Trial Profile

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aerosolized ALN-RSV01 Plus Standard of Care in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Asvasiran sodium (Primary)
Indications Bronchiolitis obliterans; Respiratory syncytial virus infections
Focus Therapeutic Use
Sponsors Alnylam Pharmaceuticals

03 Sep 2015 Results published in the Journal of Heart and Lung Transplantation
05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.
05 Sep 2012 Results presented at the 22nd Annual Congress of the European Respiratory Society.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com